Novartis looks odds on to extend the indications of its CDK4/6 inhibitor Kisqali into early-stage breast cancer, on the back of data from the phase 3 NATALEE trial reported at the ASCO congress.

Novartis, meanwhile, is also looking to muscle in on the adjuvant setting with the NATALEE trial of Kisqali, due to generate results later this year. The CDK 4/6 drug made $1.2 billion in sales ...

Lean PCOS is polycystic ovary syndrome in people of normal weight. Up to 30% of women with the condition fall into this group. But since they are in the minority and excess weight is considered a ...